Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2023-08-17 DOI:10.1111/dom.15238
Kang Chen MD, Zewei Shen MMed, Weijun Gu MD, Zhaohui Lyu MD, Xuan Qi MD, Yiming Mu MD, Yi Ning MD, for the Meinian Investigator Group
{"title":"Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults","authors":"Kang Chen MD,&nbsp;Zewei Shen MMed,&nbsp;Weijun Gu MD,&nbsp;Zhaohui Lyu MD,&nbsp;Xuan Qi MD,&nbsp;Yiming Mu MD,&nbsp;Yi Ning MD,&nbsp;for the Meinian Investigator Group","doi":"10.1111/dom.15238","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To evaluate the prevalence of overweight/obesity and associated complications from a large, cross-sectional, nationwide database in China.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Data were obtained from 519 Meinian health check-up centres across 243 cities. Eligible participants were aged ≥18 years, with a routine check-up in 2019 (N = 21 771 683) and complete height, weight, sex and region data. The unadjusted prevalence rates of overweight/obesity were calculated by age, sex and region. In addition, the nationwide prevalence rates of overweight and obesity were standardized according to the 2010 China census by age group and sex. The prevalence of obesity-related complications by body mass index (BMI) groups was calculated using logistic regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 15 770 094 eligible participants (median age 40 years; mean BMI 24.1 kg/m<sup>2</sup>; 52.8% male). By Chinese BMI classification, 34.8% were overweight and 14.1% were obese. Overweight and obesity were more prevalent in male than female participants (standardized: overweight 40.2% vs. 27.4%; obesity 17.6% vs. 9.6%, respectively). The prevalence of assessed complications was higher in participants with overweight/obesity versus those with normal BMI (<i>P</i> &lt; 0.001 for trends). The most prevalent complications in participants with overweight/obesity were fatty liver disease, prediabetes, dyslipidaemia and hypertension. The number of complications increased with higher BMI.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Overweight/obesity and related complications are highly prevalent in this population. These data may better inform management and prevention public health strategies in China.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"25 11","pages":"3390-3399"},"PeriodicalIF":5.4000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15238","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.15238","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 2

Abstract

Aim

To evaluate the prevalence of overweight/obesity and associated complications from a large, cross-sectional, nationwide database in China.

Materials and Methods

Data were obtained from 519 Meinian health check-up centres across 243 cities. Eligible participants were aged ≥18 years, with a routine check-up in 2019 (N = 21 771 683) and complete height, weight, sex and region data. The unadjusted prevalence rates of overweight/obesity were calculated by age, sex and region. In addition, the nationwide prevalence rates of overweight and obesity were standardized according to the 2010 China census by age group and sex. The prevalence of obesity-related complications by body mass index (BMI) groups was calculated using logistic regression.

Results

There were 15 770 094 eligible participants (median age 40 years; mean BMI 24.1 kg/m2; 52.8% male). By Chinese BMI classification, 34.8% were overweight and 14.1% were obese. Overweight and obesity were more prevalent in male than female participants (standardized: overweight 40.2% vs. 27.4%; obesity 17.6% vs. 9.6%, respectively). The prevalence of assessed complications was higher in participants with overweight/obesity versus those with normal BMI (P < 0.001 for trends). The most prevalent complications in participants with overweight/obesity were fatty liver disease, prediabetes, dyslipidaemia and hypertension. The number of complications increased with higher BMI.

Conclusions

Overweight/obesity and related complications are highly prevalent in this population. These data may better inform management and prevention public health strategies in China.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国肥胖及其相关并发症的患病率:1580万成年人的横断面真实世界研究
目的从中国一个大型的、横断面的、全国性的数据库中评估超重/肥胖及其相关并发症的患病率。材料与方法数据来自243个城市的519个美年健康体检中心。符合条件的参与者年龄≥18岁 年,2019年进行常规检查(N = 21 771 683)以及完整的身高、体重、性别和区域数据。未经调整的超重/肥胖患病率按年龄、性别和地区计算。此外,根据2010年中国人口普查,按年龄组和性别对全国超重和肥胖的患病率进行了标准化。体重指数(BMI)组肥胖相关并发症的发生率采用逻辑回归计算。结果共有15个 770 094名符合条件的参与者(中位年龄40岁 年;平均BMI 24.1 kg/m2;52.8%为男性)。根据中国的BMI分类,34.8%的人超重,14.1%的人肥胖。超重和肥胖在男性参与者中比女性参与者更普遍(标准化:超重分别为40.2%和27.4%;肥胖分别为17.6%和9.6%)。超重/肥胖参与者的评估并发症发生率高于BMI正常的参与者(P <; 趋势为0.001)。超重/肥胖参与者最常见的并发症是脂肪肝、糖尿病前期、血脂异常和高血压。并发症的数量随着BMI的升高而增加。结论超重/肥胖及相关并发症在该人群中非常普遍。这些数据可以更好地为中国的公共卫生管理和预防策略提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4. Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials. Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study. Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications. Relationship between trajectory of Chinese visceral adiposity index and risk of type 2 diabetes mellitus: Evidence from the China-PAR project.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1